Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at email@example.com if you need assistance.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Hear from leaders around the globe as they share insights about their experiences and lessons learned throughout their certification journey.
Posted 21 April 2017 | By Zachary Brennan
The US Food and Drug Administration (FDA) on Friday announced its fifth biosimilar approval: Samsung Bioepis’ Renflexis (infliximab-abda), an intravenous infusion for multiple indications.
This is the second FDA approval for a biosimilar to Johnson & Johnson’s Remicade (the first was Pfizer and Celltrion’s Inflectra (infliximab-dyyb)), though both Inflectra and Renflexis have been approved as biosimilars but not as interchangeable biosimilars. The shift in the cost of Remicade, with two competitors hitting the market now, could be a bellwether for how biosimilar savings are calculated.
Also on Friday, the European Medicines Agency recommended three biosimilars for approval, including Sandoz's Erelzi (etanercept), and its Rixathon (rituximab) and Riximyo (rituximab).
The most recent prior biosimilar US approval was for Amgen's Amjevita (adalimumab-atto), which was the first biosimilar version of AbbVie's best-selling biologic Humira. The third was Sandoz’s biosimilar to Amgen’s blockbuster Enbrel, known as Erelzi (etanercept-szzs), and the first biosimilar approved was Sandoz’s Zarxio (filgrastim-sndz), biosimilar to Amgen's Neupogen.
Tags: biosimilar, FDA approval
Regulatory Focus newsletters
All the biggest regulatory news and happenings.